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ABSTRACT
Asthma is characterized by chronic airway inflamma-
tion and the recruitment of inflammatory cells, typically
eosinophils and lymphocytes, into the airway.
Although several chemical mediators are released
during the inflammatory process of asthma, evidence
strongly suggests that the cysteinyl leukotrienes (LT),
LTC4, LTD4, and LTE4, play key roles in asthma. The
short-term clinical efficacy of an LT receptor antago-
nist, pranlukast hydrate, in symptomatic patients with
asthma who had already been treated with moderate
to high doses of inhaled corticosteroids was therefore
investigated. Treatment with pranlukast hydrate for 4
weeks significantly improved respiratory function and
decreased asthma symptoms, the rescue use of
inhaled b 2-agonists, the number of peripheral blood
eosinophils and serum levels of eosinophil cationic
protein. Furthermore, airway inflammation, as evalu-
ated by the percentage of eosinophils in induced
sputum and airway responsiveness to histamine,
decreased significantly after treatment. There were no
significant changes in these parameters in control
patients with asthma whose treatment was not
changed over 4 weeks. These preliminary results
suggest that pranlukast hydrate, an LT receptor antag-
onist, is an effective agent in the management of
asthma in combination with moderate to high doses of
inhaled corticosteroids.
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leukotriene receptor antagonist.
INTRODUCTION
Asthma is caused by chronic airway inflammation involv-
ing numerous inflammatory cells, including eosinophils
and lymphocytes.1 Airway inflammation, together with
epithelial desquamation, edema, hypertrophy of airway
smooth muscle and mucus glands and mucus plugging,
induces airway obstruction and enhances airway respon-
siveness in asthma.2 Although several chemical mediators
are released during chronic airway inflammation, evi-
dence strongly suggests that the cysteinyl leukotrienes (LT)
C4, D4, and E4 play key roles in asthma.3
In 1938, Feldberg and Kellaway first reported that
chemical activity in lung perfusate causes slow-onset,
sustained contraction of airway smooth muscle; these
mediators were later called slow-reacting substances 
of anaphylaxis (SRS-A).4 In 1983, the component mole-
cules of SRS-A were identified as LTC4, D4, and E4 by
Samuelsson.5 AIthough LT are produced by several types
of inflammatory cell, most cysteinyl LT are produced by
eosinophils and mast cells.6 Leukotrienes are not stored
in cells, but are newly generated from arachidonic acid
after cellular activation.
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Pharmacologic actions of cysteinyl LT include potent
bronchoconstriction, increased microvascular leakage
and mucus secretion, chemoattraction of eosinophils and
proliferation of human airway smooth muscle.7 Because
of their many actions, cysteinyl LT likely play important
roles in asthma. In fact, LT are elevated in broncho-
alveolar lavage fluid and urine during acute exacerbations
of asthma.8–10 Furthermore, challenges with allergen,
exercise, cold air inhalation and aspirin result in the
release of cysteinyl LT in asthma and antagonists of LT
significantly inhibit the bronchoconstriction in response to
these challenges.11–14 Therefore, treatment with LT modi-
fiers would be beneficial in the management of asthma.
In the present study, we investigated the short-term
effects of an LT receptor antagonist, pranlukast hydrate,
on asthma symptoms and respiratory function. Further-
more, changes in airway inflammation, as evaluated by
hypertonic saline-induced sputum and airway respon-
siveness to histamine, were examined before and after
treatment in patients with asthma who had already been
treated with moderate to high doses of inhaled corti-
costeroids.
METHODS
Subjects
Eighty patients with asthma were enrolled in this study. 
No subjects had used oral steroids or had suffered from
respiratory infections in the 4 weeks before enrolment or
during the study period. The baseline forced expiratory
volume in 1 s (FEV1) was more than 50% of the predicted
values and improved more than 15% with inhalation of a
b 2 agonist. All patients had been treated with an inhaled
corticosteroid (beclomethasone dipropionate (BDP), 800–
1200 m g/day) and bronchodilators (slow-release theo-
phylline or an inhaled b 2 agonist or both) for more than
3 months, but asthma symptoms persisted. Oral medi-
cations and inhaled corticosteroids were withheld for at
least 12 and 24 h, respectively, before each examination
visit. Plasma concentrations of theophylline in patients
receiving this drug were measured before every study and
were confirmed to be less than 5 m g/mL. Informed
consent was obtained before the study.
Study design
After a 2-week run-in period, all patients underwent
blood tests and tests of respiratory function and were 
randomly separated into two groups by an enveloped
method. One group of patients was additionally treated
with pranlukast hydrate (225 mg twice daily, ONON,
ONO Pharmaceutical Co. Ltd, Osaka, Japan), a specific
LT receptor antagonist, and the other group of patients
was treated without changes in all medications for 
4 weeks as a control. Asthma symptoms, morning peak
expiratory flow (PEF) and rescue use of b 2-agonists were
monitored. Sputum induction with hypertonic saline
inhalation and airway responsiveness to histamine were
evaluated at enrolment and at the end of the study period.
Clinical measurements
A daily record was kept of asthma symptoms, including
breathlessness and wheezing on a scale of 0–9 (0 = no
symptoms, 1 = breathlessness or wheezing, 3 = mild
asthma, 6 = moderate asthma, 9 = severe asthma);
cough on a scale of 0.5–1 (0.5 = infrequent cough, 1 =
frequent cough); and sleep disturbance on a scale of
0–12 (0 = slept well through the night, 4 = slept most 
of the night despite dyspnea, 8 = slept with difficulty
because of asthma, 12 = kept awake most of the night
by asthma). Asthma symptoms were compared on the
basis of the mean symptom scores during the observation
period and the last 2 weeks of the study period. Morning
PEF was recorded each day as the best of three succes-
sive trials with a Mini-Wright peak flow meter (Clement
Clark International Ltd, Harlow, UK).
Sputum induction and analysis
Sputum induction was performed before and after 4 weeks
of treatment, as described previously.15 Briefly, medi-
cations were stopped for at least 12 h, after which
sputum was induced by inhalation of increasing concen-
trations of hypertonic saline (0.9, 1.8, 3, 4 and 5%) until
an adequate volume of sputum was collected. Patients
were encouraged to cough deeply after each inhalation.
Cell plugs in sputum were separated from saliva and
treated with Wright-Giemsa stain so that inflammatory
cells could be counted. The percentages of eosinophils
were determined by counting 900 cells under a light
microscope.
Airway responsiveness to histamine
Airway responsiveness to histamine was measured with a
method described previously.16 Briefly, patients inhaled
normal saline, then inhaled doubling concentrations of
histamine by tidal breathing from a Devilbis nebulizer
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(Somerset, PA, USA) for 2 min until FEV1 had decreased
by more than 20% of the baseline value. Results are
expressed as the provocative concentration causing a
20% decrease in FEV1 (PC20).
Peripheral blood analysis
Eosinophils were counted and serum concentrations of
eosinophil cationic protein (ECP) were measured with
radioimmunoassay.17 Total and Der f-specific IgE anti-
body titers were measured with CAP-radioallergosorbent
test (RAST; Pharmacia Diagnostics, Uppsala, Sweden).18
Statistical analysis
The Wilcoxon test and the Mann–Whitney U-test were
used for statistical analysis. Data are expressed as the
mean ± SEM and a probability less than 0.05 was con-
sidered to indicate significance.
RESULTS
Thirty-seven patients completed the study and three
patients dropped out because of exacerbations of asthma
that required oral or intravenous steroids in pranlukast
treatment group. In the control group, 33 patients com-
pleted the study and seven patients dropped out due to
asthma exacerbation. Characteristics of patients who
completed the study are summarized in Table 1. Sputum
was successfully collected from 28 and 27 patients and
airway responsiveness to histamine was evaluated in 
34 and 30 patients in pranlukast treatment group and
control groups, respectively, before and at the end of 
the study period. There were no significant differences
between the pranlukast treatment group and the control
group in age (P = 0.233), duration of asthma (P = 0.381),
symptom score (P = 0.426), rescue use of inhaled b 2-
agonist (P = 0.50), pulmonary function including forced
vital capacity (FVC) (P = 0.36), %FVC (P = 0.503), FEV1
(P = 0.394), FEV1% (P = 0.480), maximum expiratory
flow at 25% of the FVC divided by height (V
.
25/HT; 
P = 0.724), morning PEF (P = 0.432), number of per-
ipheral blood eosinophils (P = 0.107) and serum ECP
levels (P = 0.868) at baseline.
Outcome measures are summarized in Table 2.
Although asthma symptoms continued during the obser-
vation period, treatment with pranlukast hydrate for 
4 weeks significantly decreased the severity of asthma
symptoms (4.7 ± 1.2 to 1.8 ± 0.4; P < 0.03). Signif-
icant improvements in respiratory function, including
increases in morning PEF (366 ± 17 to 389 ± 17
L/min; P < 0.01) and FEV1 (1.83 ± 0.11 to 1.95 ±
0.11 L; P < 0.01), were observed. Of the pranlukast
group patients, 51.4% had an increase of more than
10% in FEV1 after treatment with pranlukast hydrate com-
pared with 24.2% of patients in the control group (Fig. 1).
Deterioration in FEV1 was observed for 18.9% of patients
in the pranlukast group and 52.1% of patients in the
control group (Fig. 1). A marker of peripheral airway
dilatation, V
.
25/HT, increased slightly but not significantly
after treatment with pranlukast hydrate (0.46 ± 0.05 to
0.48 ± 0.04 L/min per m; P = 0.057). The rescue use
of inhaled b 2-agonists was also significantly decreased
after treatment with pranlukast hydrate (1.2 ± 0.4 to 0.3
± 0.2 puffs/week; P < 0.01). There were no significant
changes in asthma symptoms and respiratory function in
control patients with asthma.
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Table 1 Patient characteristics
Pranlukast group Control group
Number 37 33
Male/Female 22/15 17/16
Age (years) 50.8 ± 2.4 48.4 ± 2.2
Duration (years) 8.8 ± 1.6 10.9 ± 1.9
Atopy/Non-atopy 20/17 17/16
BDP dose (m g/day) 1048.6 ± 39.1 1127.3 ± 53.5
BDP, beclomethasone dipropionate.
Fig. 1 Percentage of patients with an increase or decrease in
forced expiratory volume in 1 s (FEV1) at the end of the study
period in the pranlukast (j) and control (h) groups.
Because asthma is caused by airway inflammation, 
we next investigated the effects of pranlukast hydrate on
the number of peripheral blood eosinophils, serum ECP
levels and percentages of sputum eosinophils. Treatment
with pranlukast hydrate significantly decreased the
number of peripheral blood eosinophils (437.1 ± 55.0
to 266.1 ± 30.9 / m L; P < 0.01), serum ECP levels
(27.9 ± 5.8 to 18.1 ± 2.1 ng/mL; P < 0.03) and the
percentages of sputum eosinophils (26.1 ± 3.2 to 18.9
± 3.6%; P < 0.01; Fig. 2). Furthermore, airway respon-
siveness to histamine was significantly decreased after
treatment with pranlukast hydrate (715.3 ± 228.3 to
1404.2 ± 401.1 m g/mL; P < 0.01; Fig. 3). There was
no significant change in the number of peripheral blood
eosinophils, the serum ECP levels, the percentages of
sputum eosinophils and airway responsiveness to hista-
mine in control patients with asthma (Table 2, Figs 2,3).
DISCUSSION
In this preliminary study, we have demonstrated that treat-
ment with pranlukast hydrate, an LT receptor antagonist,
significantly improves respiratory function and decreases
asthma symptoms, airway inflammation and airway
hyperresponsiveness in patients with asthma. Although
our study was parallel and not a placebo-controlled
design, it clearly shows that short-term treatment with this
LT receptor antagonist significantly decreases airway
inflammation and airway hyperresponsiveness. Further-
more, our results suggest that a LT receptor antagonist
would be effective against asthma that was not com-
pletely controlled with moderate to high doses of inhaled
corticosteroids.
Because the pathogenesis of asthma is chronic airway
inflammation, guidelines for the treatment of asthma in
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Table 2 Outcome measures
Pranlukast group Control group
Before After P value Before After P value
Symptom score 4.7 ± 1.2 1.8 ± 0.4 <0.03 3.6 ± 0.6 4.0 ± 0.7 NS
(score/week)
Rescue use of inhaled 1.2 ± 0.37 0.3 ± 0.2 <0.01 1.6 ± 0.4 2.0 ± 0.5 NS
b 2-agonist (puffs/week)
Pulmonary function
FVC (L) 2.41 ± 0.13 2.57 ± 0.15 NS 2.57 ± 0.12 2.64 ± 0.15 NS
%FVC 83.7 ± 3.65 85.6 ± 3.05 NS 86.5 ± 2.29 88.7 ± 2.68 NS
FEV1 (L) 1.83 ± 0.11 1.95 ± 0.11 <0.01 1.96 ± 0.10 1.92 ± 0.10 NS
FEV1% 74.3 ± 1.64 74.7 ± 2.11 NS 75.8 ± 1.51 74.8 ± 1.65 NS
V
.
25/HT (L/s per m) 0.46 ± 0.05 0.48 ± 0.04 0.056 0.48 ± 0.04 0.46 ± 0.04 NS
Morning PEF (L/min) 366 ± 17 389 ± 17 <0.01 386 ± 18 394 ± 17 NS
Blood analysis
Eosinophils(/m L) 437.1 ± 55.0 266.1 ± 30.9 <0.01 318.2 ± 43.2 321.2 ± 34.2 NS
Serum ECP(ng/mL) 27.9 ± 5.8 18.1 ± 2.1 <0.03 27.0 ± 2.1 23.9 ± 2.4 NS
FVC, forced vital capacity; FEV1, forced expiratory volume in 1 s; V
.
25/HT, maximum expiratory flow at 25% of the FVC divided by height; PEF,
peak expiratory flow; ECP, eosinophil cationic protein; NS, not significant.
Fig. 2 Effects of pranlukast
hydrate on the percentage of
sputum eosinophils. The per-
centage of sputum eosinophils
was measured during the obser-
vation period and at the end of
the study period in pranlukast
and control groups. NS, not 
significant.
Japan and other countries suggest that inhaled corti-
costeroids be used as the central agent in the treatment 
of mild to severe asthma.19–21 Recently, the Expert Panel
Report II of the National Heart, Lung and Blood Institute
stated that treatment with LT modifiers, such as LT recep-
tor antagonists and 5-lipoxygenase inhibitors, may be
considered an alternative to low-dose inhaled corti-
costeroid therapy for patients with mild persistent
asthma.20 In contrast, Japanese guidelines suggest that 
LT receptor antagonists be used to treat not only mild 
persistent to moderate asthma but also severe asthma.19
Recent studies have shown that LT modifiers have
inhibitory effects in clinical models of asthma, includ-
ing allergen-induced, exercise-induced, cold air hyper-
ventilation-induced and aspirin-induced asthma.11–14
These results suggest that leukotriene modifiers may be
useful for treating aspirin-induced asthma and exercise-
induced asthma. Although LT modifiers have been
reported to reduce symptoms, improve air flow, and
reduce the rescue use of inhaled b 2-agonists in asthma,
their effects on airway inflammation and airway hyper-
responsiveness have not been fully investigated.
The finding that activated eosinophils and mast cells
play important roles in asthma suggests that persistent gen-
eration of cysteinyl LT is a consequence of persistent airway
inflammation. Several reports have confirmed that cysteinyl
LT cause eosinophil chemotaxis in vitro.22,23 In addition,
inhalation of LTE4 increases the number of eosinophils in
human bronchial biopsy specimens.24 In the present study,
we have demonstrated that short-term treatment of mod-
erate to severe asthma with an LT receptor antagonist
significantly decreases the percentage of eosinophils in
induced sputum and serum ECP levels. In addition, we
have found in a recent double-blind, placebo-controlled
trial that MK-476, another LT receptor antagonist, signifi-
cantly decreases the number of sputum eosinophils in
patients with mild to moderate asthma.25 These results
suggest that cysteinyl LT may be involved in airway
eosinophilia in asthma.
Airway hyperresponsiveness is also a characteristic of
asthma. Inhaled cysteinyl LT have been shown to induce
airway hyperresponsiveness.26,27 In addition, several
clinical studies suggest that antagonists of cysteinyl 
LT can block airway hyperresponsiveness. One study
has shown that treatment with pranlukast hydrate, an 
LT receptor antagonist, for 1 week decreased airway
responsiveness to methacholine and another report has
shown that treatment with a 5-lipoxygenase inhibitor,
zileuton, for 13 weeks decreased airway responsiveness
to cold air.28,29 In the present study, we have demon-
strated that treatment with pranlukast hydrate for 4 weeks
decreased both airway inflammation and airway hyper-
responsiveness in patients with moderate to severe
asthma. Because baseline FEV1 was also increased after
treatment with pranlukast hydrate, we cannot conclude
that the resolution of airway inflammation was the only
cause of the decreased airway hyperresponsiveness. In
addition, although improvement of airway responsive-
ness to histamine was statistically significant, it remains
unknown how this improvement might contribute to the
clinical efficacy of this drug.
Several studies that have measured clinical outcome
have shown that some patients respond to LT modifiers. 
If an increase in FEV1 of more than 10% after treatment 
is used as a cut-off point, 19 of the 37 patients (51.4%) 
in the present study were responders. Although the 
mean decrease in sputum eosinophils in responders
(11.2 ± 2.9%) was greater than that in non-responders
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Fig. 3 Effects of pranlukast
hydrate on airway responsive-
ness to histamine. Airway res-
ponsiveness to histamine was
assessed during the observation
period and at the end of the
study period of the pranlukast
and control groups. Results are
expressed as the provocative
concentration causing a 20%
decrease in the forced expira-
tory volume in 1 s (PC20). NS,
not significant.
(3.26 ± 5.11%), it was not statistically significant 
(P = 0.056). These results suggest that the LT receptor
antagonist pranlukast hydrate has both bronchodilator
and anti-inflammatory effects in responders.
In summary, our results provide biological proof that 
LT are important mediators in asthma and that an LT recep-
tor antagonist, pranlukast hydrate, is a useful agent for
patients with symptomatic asthma who have been treated
with moderate to high doses of inhaled corticosteroids.
Therefore, we conclude that the addition of a LT receptor
antagonist to treatment with inhaled corticosteroids is
beneficial in patients with moderate to severe asthma.
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